BERKELEY HEIGHTS, NJ - October 26, 2006-
Genta Incorporated (NASDAQ: GNTA) announced that the Company
will release its Third Quarter 2006 financial results on Tuesday,
November 7, 2006. Dr. Raymond P. Warrell, Jr., Chairman and Chief
Executive Officer, joined by Richard Moran, Senior Vice President
and Chief Financial Officer, will host a conference call and live
audio webcast to discuss financial results and recent corporate
activities at 8:00 am EDT.
Conference call information:
US/Canada call: 877-634-8606; conference code Genta Incorporated
International call: 706-679-3140; conference code Genta
Incorporated
Webcast:
http://www.genta.com/genta/InvestorRelation/events.html
Audio replay will be available approximately two hours after the
completion of the call, and will be archived for 30 days. Access
numbers for this replay are: (800) 642-1687 (U.S./Canada) and (706)
645-9291 (International); conference ID number is: 8803694.
About Genta
Genta Incorporated is a biopharmaceutical company with a
diversified product portfolio that is focused on delivering
innovative products for the treatment of patients with cancer. The
Company's research platform is anchored by two major programs that
center on oligonucleotides (RNA- and DNA-based medicines) and small
molecules. Genasense® (oblimersen sodium) Injection is the
Company's lead compound from its oligonucleotide program. The
Company has submitted a New Drug Application (NDA) to the Food and
Drug Administration for the use of Genasense plus fludarabine and
cyclophosphamide for treatment of patients with relapsed or
refractory chronic lymphocytic leukemia (CLL). Genta has completed
a Marketing Authorization Application to the European Medicines
Agency (EMEA) for use of Genasense plus dacarbazine for treatment
of patients with advanced melanoma. Genta has additional randomized
clinical trials ongoing in patients with acute myeloid leukemia,
hormone-refractory prostate cancer, and lung cancer. The leading
drug in Genta's small molecule program is Ganite® (gallium nitrate
injection), which the Company is exclusively marketing in the U.S.
for treatment of symptomatic patients with cancer related
hypercalcemia that is resistant to hydration. For more information
about Genta, please visit our website at:
http://www.genta.com/
.
SAFE HARBOR
This press release and the conference call to follow contain
forward-looking statements with respect to business conducted by
Genta Incorporated. By their nature, forward-looking statements
and forecasts involve risks and uncertainties because they relate
to events and depend on circumstances that will occur in the
future. Forward-looking statements include, without limitation,
statements about:
-
the Company's ability to obtain necessary regulatory
approval for Genasense® from the U.S. Food and Drug
Administration ("FDA") or European Medicines Agency
("EMEA");
-
the safety and efficacy of the Company's products or
product candidates;
-
the Company's assessment of its clinical trials;
-
the commencement and completion of clinical trials;
-
the Company's ability to develop, manufacture, license and
sell its products or product candidates;
-
the Company's ability to enter into and successfully
execute license and collaborative agreements, if any;
-
the adequacy of the Company's capital resources and cash
flow projections, and the Company's ability to obtain
sufficient financing to maintain the Company's planned
operations;
-
the adequacy of the Company's patents and proprietary
rights;
-
the impact of litigation that has been brought against the
Company and its officers and directors; and
-
the other risks described under Certain Risks and
Uncertainties Related to the Company's Business, as contained
in the Company's Annual Report on Form 10-K and Quarterly
Report on Form 10-Q.
The Company does not undertake to update any forward-looking
statements. There are a number of factors that could cause actual
results and developments to differ materially. For a discussion
of those risks and uncertainties, please see the Company's Annual
Report on Form 10-K for 2005 and its most recent quarterly report
on Form 10-Q.
SOURCE: Genta Incorporated
CONTACTS:
Investor Relations
Tara Spiess/Andrea Romstad
TS Communications Group, LLC
info@genta.com
(908) 286-3980
